Glenmark Pharmaceuticals has announced the launch of Ryaltris-AZ mometasone furoate / azelastine nasal spray for the treatment of allergic rhinitis in India, touting the low cost of the nasal spray compared to similar products. According to Glenmark, Ryaltris-AZ is priced at slightly less than half the cost of “the average price of the top 10 brands of the similar drug category in the market.”
Over the past few years, the company has launched Ryaltris olopatadine / mometasone furoate nasal spray for the treatment of allergic rhinitis in several countries, including Australia, Russia, South Africa, Ukraine, and Uzbekistan and recently announced the launch of that product in Europe.
Glenmark Group VP & Business Head, India Formulations, Alok Malik commented, “Glenmark has been a pioneer in providing access to the latest treatment options for respiratory disease patients in India. We are glad to introduce our brand Ryaltris-AZ, which is clinically studied and cutting-edge, at an affordable cost for patients in the country. Respiratory segment is a key area of focus for Glenmark and the launch of this product will enable us to improve access to allergic rhinitis treatment by providing an effective, convenient, world-class and affordable treatment option to patients in India.”
Read the Glenmark Pharmaceuticals press release.
